GLP‐1 agonists already used in obesity treatment, semaglutide and liraglutide, are engineered with fatty‐acid acylation to prevent degradation by oligomer forming, with semaglutide additionally undergoing N‐terminal modification to further inhibit DPP‐4 proteolysis.27 Here, GLP1R is linked to obesity disorder.